Monkeypox Treatment Market Analysis & Forecast: 2026-2033
The monkeypox treatment market was valued at USD 134.8 Mn in 2026 and is forecast to reach a value of USD 422.4 Mn by 2033 at a CAGR of 18.5% between 2026 and 2033.
Two outbreaks of a disease resembling the pox in colonies of monkeys kept for research led to the discovery of monkeypox in 1958. The monkeypox virus is the cause of this rare viral disease. Monkeypox is a type of Zoonotic disease, which are transmitted from animals to humans. The virus that causes smallpox and monkeypox both belong to the same family of viruses. However, it is less severe as compared to smallpox. The symptoms of monkeypox are similar to smallpox symptoms, but are milder and generally non-fatal.
|
Current Event |
Description and its Impact |
|
Expansion of Monkeypox Vaccination Programs |
|
|
Regulatory Approvals and Launches of Antiviral Treatments |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of treatment type, the prophylactic (vaccines) segment is expected to lead the market with 75% share in 2026, this leadership can primarily be attributed to the global emphasis on preventive healthcare measures and the critical role vaccines play in curbing disease transmission. Vaccination campaigns have historically been central to controlling orthopoxvirus outbreaks, including smallpox, a close relative of monkeypox, demonstrating the proven effectiveness of prophylactic immunization strategies.
For instance, in December 2025, the U.S. Centers for Disease Control and Prevention (CDC) have emphasized the utilization of the Jynneos vaccine, a non-replicating smallpox and monkeypox vaccine approved by the FDA for prevention of monkeypox in high-risk populations. The installation of this vaccine has been instrumental in lowering new infection rates, particularly among healthcare workers as well as communities with a high exposure risk.
In terms of route of administration, the injectable segment is expected to hold 65% share of the market in 2026. This dominance by the Injectable segment can primarily be attributed to the urgency and severity associated with monkeypox infections, which usually necessitate rapid therapeutic intervention achievable through parenteral administration. Injectable treatments, such as intravenous or intramuscular formulations, facilitate faster bioavailability as well as more controlled dosing compared to oral medications, enabling them preferred in clinical settings, especially for moderate to severe cases.
For instance, antiviral agents such as Tecovirimat (TPOXX), which has been authorized for treatment of orthopoxvirus infections including monkeypox, are usually administered via injection in hospital environments to ensure immediate plasma concentrations that can potentially suppress viral replication. The U.S. Centers for Disease Control and Prevention (CDC) as well as the World Health Organization (WHO) have highlighted the necessity of timely administration of injectable antivirals for outbreak control, showing the preference for this route in clinical protocols.
In terms of route of administration, the hospital pharmacies segment is projected to account for 60% share of the market in 2026. Owing to their pivotal role in the management and dispensation of critical medications, particularly for infectious diseases such as monkeypox, which often require immediate and specialized treatment within controlled healthcare environments. Hospital pharmacies are embedded within healthcare facilities where patients with confirmed or suspected monkeypox infections receive care under close medical supervision, making these pharmacies the primary source of supply for antiviral treatments, supportive care drugs, and essential medications to manage symptoms and complications associated with the infection.
To learn more about this report, Download Free Sample
North America is expected to dominate the Monkeypox Treatment market with 43% share in 2026. This is because the region has strong healthcare systems, active government programs, as well as high awareness of infectious diseases. The Centers for Disease Control and Prevention (CDC) in the United States has helped quickly identify and manage Monkeypox cases, increasing the need for effective treatments.
For instance, in 2025, the USA reported about 2,042 Monkeypox cases, far below 200,000. This low number and the seriousness of the disease mean that treatments like NV-387 qualify for Orphan Drug Designation, encouraging faster development and availability of therapies.
Asia Pacific is expected to exhibit the fastest growth, driven by multiple converging factors including the heightened disease incidence rates, escalating governmental focus on infectious disease management, as well as increased healthcare spending. Significant outbreaks reported in countries such as India, Thailand, and the Philippines have underscored the urgent need for scalable as well as accessible treatment alternatives, which in turn has galvanized local and regional efforts to strengthen healthcare delivery around Monkeypox.
For instance, in October 2025, collaborated to develop a new Monkeypox (mpox) vaccine. The vaccine utilized a live-attenuated virus as well as was developed through clinical research and manufacturing support. This collaboration supported the growth of vaccines in the Monkeypox Treatment market, especially in the Asia-Pacific region.
The U.S. contributes the highest share in the Monkeypox Treatment Market due to its advanced healthcare infrastructure, extensive research and development activities, as well as robust support by government authorities in managing infectious diseases. The U.S. Centers for Disease Control and Prevention (CDC) has been at the forefront of examining monkeypox outbreaks as well as facilitating access to therapeutics, which underscores the country’s leadership role in this segment.
According to recent announcements from the CDC, the U.S. government ramped up federal procurement of such treatments during the 2022-2023 monkeypox public health emergency, demonstrating both preparedness as well as the ability to instantly deploy treatment resources.
Japan contributes the highest share in the Monkeypox Treatment Market owing to its well-established healthcare infrastructure, advanced pharmaceutical research capabilities, as well as a robust government-led public health response system. Japan’s healthcare system is recognized for its efficiency and extensive coverage, enabling rapid diagnosis, treatment, as well as containment of infectious diseases like Monkeypox.
For instance, in January 2025, SIGA Technologies announced that its antiviral drug TEPOXX (tecovirimat) was approved in Japan. TEPOXX can treat smallpox, Monkeypox (mpox), cowpox, and problems after smallpox vaccination in adults and children weighing at least 13 kg. It is the first antiviral approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for treating orthopoxviruses.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 134.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 18.5% | 2033 Value Projection: | USD 422.4 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
SIGA Technologies Inc., Bavarian Nordic, Sanofi SA., Emcure Pharma, Jinan Jinda Pharmaceutical Chemistry Co., Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The escalating global incidence of monkeypox outbreaks has emerged as a critical catalyst propelling the monkeypox treatment market forward, fundamentally reshaping pharmaceutical priorities and healthcare preparedness strategies worldwide. The outbreak patterns have demonstrated the virus's potential for sustained human-to-human transmission in non-endemic countries, particularly affecting vulnerable populations and creating urgent demand for effective therapeutic interventions.
The escalating focus of worldwide by governments authorities on infectious disease research has played a pivotal role in propelling the development and availability of treatments for emerging and re-emerging pathogens, including Monkeypox. In response to recent outbreaks and the potential for wider spread, several governments have amplified their budgetary commitments to infectious disease control and research, recognizing the importance of preparedness as well as containment.
The development of novel targeted antiviral therapies presents a substantial as well as transformative opportunity in the Monkeypox treatment market, primarily due to the increasing incidence and geographic spread of the disease in recent years. Novel antivirals that target viral replication mechanisms or specific viral proteins can offer more effective treatment outcomes, reduce disease severity, and limit transmission.
The Monkeypox Treatment Market is gaining significant attention due to the rising incidence of monkeypox outbreaks globally. A major driver propelling the market is the high occurrence of zoonotic diseases, along with bolstering awareness as well as improved diagnostic capabilities.
This has led to more demand for effective antiviral therapies as well as supportive treatments specifically targeting monkeypox infections. Moreover, governments authorities and healthcare organizations are investing in research and stockpiling antiviral drugs, which is further surge market growth.
However, the market faces challenges such as limited availability of specifically approved monkeypox treatments as well as insufficient clinical data on the efficacy and safety of existing antivirals. These factors restrain the high use of particular treatment alternatives. Additionally, the stigma associated with contagious diseases can impede timely diagnosis as well as treatment, limiting market penetration.
Opportunities within the market are substantial, particularly with advancements in viral genomics as well as drug repurposing strategies. Companies targeting on developing broad-spectrum antivirals or vaccine adjunct therapies are well established to capitalize on these trends.
North America currently dominates the market, bolstered by well-developed healthcare infrastructure, support by governmental authorities, as well as utilization of novel therapies. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, due to rising public health initiatives as well as rising awareness about zoonotic infections.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
